Reinduction of hedgehog inhibitors after checkpoint inhibition in advanced basal cell carcinoma: a series of 12 patients

For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: DeTemple, Viola (VerfasserIn) , Hassel, Jessica C. (VerfasserIn) , Sachse, Michael M. (VerfasserIn) , Grimmelmann, Imke (VerfasserIn) , Leiter, Ulrike (VerfasserIn) , Gebhardt, Christoffer (VerfasserIn) , Eckardt, Julia (VerfasserIn) , Pföhler, Claudia (VerfasserIn) , Angela, Yenny (VerfasserIn) , Hübbe, Hanna (VerfasserIn) , Gutzmer, Ralf (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 7 November 2022
In: Cancers
Year: 2022, Jahrgang: 14, Heft: 21, Pages: 1-9
ISSN:2072-6694
DOI:10.3390/cancers14215469
Online-Zugang:Resolving-System, Volltext: https://doi.org/10.3390/cancers14215469
Verlag, Volltext: https://www.mdpi.com/2072-6694/14/21/5469
Volltext
Verfasserangaben:Viola K. DeTemple, Jessica C. Hassel, Michael M. Sachse, Imke Grimmelmann, Ulrike Leiter, Christoffer Gebhardt, Julia Eckardt, Claudia Pföhler, Yenny Angela, Hanna Hübbe and Ralf Gutzmer
Beschreibung
Zusammenfassung:For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure.
Beschreibung:Gesehen am 26.01.2023
Beschreibung:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers14215469